vs

Side-by-side financial comparison of Hippo Holdings Inc. (HIPO) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

Hippo Holdings Inc. is the larger business by last-quarter revenue ($120.4M vs $76.4M, roughly 1.6× PROCEPT BioRobotics Corp). Hippo Holdings Inc. runs the higher net margin — 5.0% vs -39.1%, a 44.1% gap on every dollar of revenue. On growth, Hippo Holdings Inc. posted the faster year-over-year revenue change (18.2% vs 11.9%). Hippo Holdings Inc. produced more free cash flow last quarter ($9.1M vs $-12.2M). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (31.0% CAGR vs 18.9%).

Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

HIPO vs PRCT — Head-to-Head

Bigger by revenue
HIPO
HIPO
1.6× larger
HIPO
$120.4M
$76.4M
PRCT
Growing faster (revenue YoY)
HIPO
HIPO
+6.2% gap
HIPO
18.2%
11.9%
PRCT
Higher net margin
HIPO
HIPO
44.1% more per $
HIPO
5.0%
-39.1%
PRCT
More free cash flow
HIPO
HIPO
$21.3M more FCF
HIPO
$9.1M
$-12.2M
PRCT
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
31.0%
18.9%
HIPO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HIPO
HIPO
PRCT
PRCT
Revenue
$120.4M
$76.4M
Net Profit
$6.0M
$-29.8M
Gross Margin
60.6%
Operating Margin
5.6%
-40.6%
Net Margin
5.0%
-39.1%
Revenue YoY
18.2%
11.9%
Net Profit YoY
-86.4%
-58.3%
EPS (diluted)
$0.31
$-0.54

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HIPO
HIPO
PRCT
PRCT
Q4 25
$120.4M
$76.4M
Q3 25
$120.6M
$83.3M
Q2 25
$117.3M
$79.2M
Q1 25
$110.3M
$69.2M
Q4 24
$101.9M
$68.2M
Q3 24
$95.5M
$58.4M
Q2 24
$89.6M
$53.4M
Q1 24
$85.1M
$44.5M
Net Profit
HIPO
HIPO
PRCT
PRCT
Q4 25
$6.0M
$-29.8M
Q3 25
$98.1M
$-21.4M
Q2 25
$1.3M
$-19.6M
Q1 25
$-47.7M
$-24.7M
Q4 24
$44.2M
$-18.9M
Q3 24
$-8.5M
$-21.0M
Q2 24
$-40.5M
$-25.6M
Q1 24
$-35.7M
$-26.0M
Gross Margin
HIPO
HIPO
PRCT
PRCT
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Q1 24
56.2%
Operating Margin
HIPO
HIPO
PRCT
PRCT
Q4 25
5.6%
-40.6%
Q3 25
81.3%
-27.8%
Q2 25
3.4%
-28.0%
Q1 25
-41.3%
-39.7%
Q4 24
46.3%
-28.9%
Q3 24
-5.4%
-38.4%
Q2 24
-40.7%
-50.3%
Q1 24
-38.7%
-62.1%
Net Margin
HIPO
HIPO
PRCT
PRCT
Q4 25
5.0%
-39.1%
Q3 25
81.3%
-25.7%
Q2 25
1.1%
-24.7%
Q1 25
-43.2%
-35.8%
Q4 24
43.4%
-27.6%
Q3 24
-8.9%
-35.9%
Q2 24
-45.2%
-48.0%
Q1 24
-42.0%
-58.3%
EPS (diluted)
HIPO
HIPO
PRCT
PRCT
Q4 25
$0.31
$-0.54
Q3 25
$3.77
$-0.38
Q2 25
$0.05
$-0.35
Q1 25
$-1.91
$-0.45
Q4 24
$1.81
$-0.34
Q3 24
$-0.34
$-0.40
Q2 24
$-1.64
$-0.50
Q1 24
$-1.47
$-0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HIPO
HIPO
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$218.3M
$286.5M
Total DebtLower is stronger
$51.6M
Stockholders' EquityBook value
$436.1M
$365.9M
Total Assets
$1.9B
$508.1M
Debt / EquityLower = less leverage
0.14×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HIPO
HIPO
PRCT
PRCT
Q4 25
$218.3M
$286.5M
Q3 25
$247.7M
$294.3M
Q2 25
$198.9M
$302.7M
Q1 25
$140.9M
$316.2M
Q4 24
$197.6M
$333.7M
Q3 24
$191.2M
$196.8M
Q2 24
$175.9M
$214.1M
Q1 24
$223.4M
$225.6M
Total Debt
HIPO
HIPO
PRCT
PRCT
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Q1 24
$51.4M
Stockholders' Equity
HIPO
HIPO
PRCT
PRCT
Q4 25
$436.1M
$365.9M
Q3 25
$421.5M
$380.3M
Q2 25
$332.5M
$385.8M
Q1 25
$322.8M
$389.2M
Q4 24
$362.1M
$402.2M
Q3 24
$326.4M
$241.2M
Q2 24
$322.6M
$251.8M
Q1 24
$351.2M
$264.0M
Total Assets
HIPO
HIPO
PRCT
PRCT
Q4 25
$1.9B
$508.1M
Q3 25
$1.9B
$511.5M
Q2 25
$1.7B
$513.1M
Q1 25
$1.5B
$519.4M
Q4 24
$1.5B
$534.0M
Q3 24
$1.5B
$374.1M
Q2 24
$1.5B
$374.4M
Q1 24
$1.5B
$382.9M
Debt / Equity
HIPO
HIPO
PRCT
PRCT
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×
Q1 24
0.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HIPO
HIPO
PRCT
PRCT
Operating Cash FlowLast quarter
$9.2M
$-10.3M
Free Cash FlowOCF − Capex
$9.1M
$-12.2M
FCF MarginFCF / Revenue
7.6%
-15.9%
Capex IntensityCapex / Revenue
0.1%
2.4%
Cash ConversionOCF / Net Profit
1.53×
TTM Free Cash FlowTrailing 4 quarters
$14.8M
$-58.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HIPO
HIPO
PRCT
PRCT
Q4 25
$9.2M
$-10.3M
Q3 25
$16.9M
$-6.6M
Q2 25
$24.7M
$-15.0M
Q1 25
$-35.6M
$-17.0M
Q4 24
$47.5M
$-32.4M
Q3 24
$46.8M
$-18.8M
Q2 24
$-10.6M
$-15.7M
Q1 24
$17.7M
$-32.3M
Free Cash Flow
HIPO
HIPO
PRCT
PRCT
Q4 25
$9.1M
$-12.2M
Q3 25
$16.8M
$-9.5M
Q2 25
$24.6M
$-17.8M
Q1 25
$-35.7M
$-18.8M
Q4 24
$47.2M
$-33.6M
Q3 24
$-19.0M
Q2 24
$-10.7M
$-16.8M
Q1 24
$17.6M
$-34.2M
FCF Margin
HIPO
HIPO
PRCT
PRCT
Q4 25
7.6%
-15.9%
Q3 25
13.9%
-11.4%
Q2 25
21.0%
-22.5%
Q1 25
-32.4%
-27.2%
Q4 24
46.3%
-49.2%
Q3 24
-32.6%
Q2 24
-11.9%
-31.4%
Q1 24
20.7%
-76.9%
Capex Intensity
HIPO
HIPO
PRCT
PRCT
Q4 25
0.1%
2.4%
Q3 25
0.1%
3.4%
Q2 25
0.1%
3.5%
Q1 25
0.1%
2.7%
Q4 24
0.3%
1.7%
Q3 24
0.0%
0.4%
Q2 24
0.1%
2.0%
Q1 24
0.1%
4.4%
Cash Conversion
HIPO
HIPO
PRCT
PRCT
Q4 25
1.53×
Q3 25
0.17×
Q2 25
19.00×
Q1 25
Q4 24
1.07×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HIPO
HIPO

Segment breakdown not available.

PRCT
PRCT

Hand Pieces And Other Consumables$34.1M45%
System Sales And Rentals$27.5M36%
Other$9.8M13%
Service Revenue$5.0M7%

Related Comparisons